# US 2021/0278419 A1 · Compositions and Methods for Identifying and Modulating Metabolic Health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0278419 A1
- Document ID: US20210278419A1
- Status: Published application
- Kind: A1
- Application number: 17/200,886
- Filed: 2021-03-14
- Published: 2021-09-09
- Earliest claimed: 2015-03-17
- Assignees: Duke University
- Applicants: Duke University
- Inventors: John F. Rawls; James E.N. Minchin
- Web page: https://patentgrep.com/patent/US20210278419A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 39/39541: {against normal tissues, cells}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method of identifying a subject at risk for metabolic dysfunction, the method comprising:
(a) isolating a biosample from a subject;
(b) determining a level of one or more biomarkers present in the biosample, wherein the one or more biomarkers comprise PlexinD1 nucleic acid, COL5A1 nucleic acid, visceral adipose tissue, subcutaneous adipose tissue, hypertrophic visceral adipose tissue, hyperplastic visceral adipose tissue, or a combination thereof; and
(c) identifying the subject as having a risk for metabolic dysfunction when the concentration of the one or more biomarkers is increased or decreased relative to a reference concentration or range of the same biomarker, and wherein the metabolic dysfunction comprises insulin sensitivity, insulin resistance, or type 2 diabetes.

### Claim 30 (depends on 29)

The method of claim 29, wherein the one or more biomarkers comprises at least two biomarkers.

### Claim 31 (depends on 29)

The method of claim 29, wherein the one or more biomarkers comprises a ratio of biomarkers.

### Claim 32 (depends on 31)

The method of claim 31, wherein the ratio of biomarkers comprises a level of visceral adipose tissue and a level of subcutaneous adipose tissue.

### Claim 33 (depends on 29)

The method of claim 29, wherein the metabolic dysfunction is insulin sensitivity.

### Claim 34 (depends on 29)

The method of claim 29, wherein the metabolic dysfunction is insulin resistance.

### Claim 35 (depends on 29)

The method of claim 29, wherein the metabolic dysfunction is type 2 diabetes.

### Claim 36 (depends on 29)

The method of claim 29, wherein the biosample comprises a biopsy material, adipose tissue, bone marrow, blood, blood plasma, serum or a cellular fraction thereof, urine, feces, saliva, tears, or cells derived from a biological source.

### Claim 37 (depends on 29)

The method of claim 29, wherein determining the level of the one or more biomarkers comprises using PCR, RT-PCR, ELISA, immunolabeling, in situ hybridization, or nucleic acid sequencing.

### Claim 38

A method for determining the efficacy of a treatment of a metabolic dysfunction in a subject, the method comprising:
(a) isolating a biosample from a subject prior to treatment of a metabolic dysfunction and determining a pre-treatment concentration of one or more biomarkers present in the biosample, wherein the one or more biomarkers comprise COL1A2, COL2A1, COL4A1, COL5A2, COL5A3, COL6A1, FN1, ACAN, LAMA, GPC4, or SPARC nucleic acid or protein,
(b) isolating a biosample from the subject after treatment of the metabolic dysfunction and determining a post-treatment concentration of the one or more biomarkers present in the biosample; and
(c) determining the efficacy of the treatment for the metabolic dysfunction when the post-treatment concentration of the one or more biomarkers is increased or decreased as compared to (1) the pre-treatment concentration of the same biomarker in the subject, or (2) a reference concentration or range of the same biomarker, wherein the metabolic dysfunction comprises insulin sensitivity, insulin resistance or type 2 diabetes.

### Claim 39 (depends on 38)

The method of claim 38, wherein the reference concentration or range of the one or more biomarkers is derived from a population of healthy subjects.

### Claim 40 (depends on 38)

The method of claim 38, wherein the treatment is effective when the concentration of the one or more biomarkers in the biosample of step (b) is decreased or lower relative to the concentration of the one or more biomarkers in the biosample of step (a), or the post-treatment concentration is within an acceptable range of the reference concentration or range.

### Claim 41 (depends on 38)

The method of claim 38, wherein the treatment is effective when the concentration of the one or more biomarkers in the biosample of step (b) is increased or higher relative to the concentration of the one or more biomarkers in the biosample of step (a), or the post-treatment concentration is within an acceptable range of the reference concentration or range.

### Claim 42 (depends on 38)

The method of claim 38, further comprising determining a level of one or more of the following in the pre-treatment biosample:
(a) a concentration of visceral adipose tissue (VAT),
(b) a concentration of subcutaneous adipose tissue (SAT),
(c) a VAT to SAT ratio,
(d) a concentration of hypertrophic VAT,
(e) or a concentration of hyperplastic VAT

### Claim 43 (depends on 42)

The method of claim 42, further comprising determining a level of one or more of the following in the post-treatment biosample:
(a) a concentration of visceral adipose tissue (VAT) that is increased or higher relative to the pre-treatment concentration of VAT, or that is within an acceptable range of the reference concentration or range;
(b) a concentration of subcutaneous adipose tissue (SAT) that is decreased or lower relative to the pre-treatment concentration of SAT, or that is within an acceptable range of the reference concentration or range;
(c) a VAT to SAT ratio that is increased or higher relative to the pre-treatment VAT to SAT ratio, or that is within an acceptable range of the reference VAT to SAT ratio or range;
(d) a concentration of hypertrophic VAT that is increased or higher relative to the pre-treatment concentration of hypertrophic VAT, or that is within an acceptable range of the reference concentration or range; or
(e) a concentration of hyperplastic VAT that is decreased or lower relative to the pre-treatment concentration of hyperplastic VAT, or that is within an acceptable range of the reference concentration or range.

### Claim 44 (depends on 38)

The method of claim 38, wherein the biosample comprises biopsy material, adipose tissue, bone marrow samples, blood, blood plasma, serum or cellular fraction thereof, urine, feces, saliva, or cells derived from a biological source.

### Claim 45 (depends on 38)

The method of claim 38, wherein the biosample comprises serum or plasma from the subject.

### Claim 46 (depends on 38)

The method of claim 38, wherein the metabolic dysfunction is insulin sensitivity.

### Claim 47 (depends on 38)

The method of claim 38, wherein the metabolic dysfunction is insulin resistance.

### Claim 48 (depends on 38)

The method of claim 38, wherein the metabolic dysfunction is type 2 diabetes.
